TORONTO, Feb. 23 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI) today
announced that it presented new findings demonstrating the clinical utility of
its EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for the
measurement of endotoxin, at the 13th Annual Critical Care for Endotoxemia
congress. The conference took place in Tokyo, Japan on February 19th and 20th,
2009 and focused on the role of endotoxemia in sepsis. In addition to
Spectral's presentation, data was presented from the Italian Critical Care
Nephrology Study Group showing the Toraymyxin(TM) cartridge, which removes
endotoxin from the bloodstream, significantly improves organ function. Prof M.
Ranieri (Turin, Italy) also presented data showing significant improvement in
kidney function in septic patients when endotoxin was removed using the
Toraymyxin cartridge. The first reported experience from India also showed
"This meeting attracts critical care physicians from many parts of Asia,
including Korea and India. Many of the presentations at this important
conference use data collected with Spectral's EAA(TM) and highlight the value
of our product, both independently and in combination with anti-endotoxin
therapies," said Dr. Paul Walker, President and CEO of Spectral. "Data from
these studies assists us as we develop the clinical pathway for the
development of our combined EAA(TM) and the Toraymyxin(TM) cartridge product
in the United States."
Debra Foster, Director of Spectral's Sepsis Program, presented data on
the use of EAA(TM) in the management of intra-abdominal sepsis following
surgical intervention. Following the conference, these findings will be
published in the Japan Journal for Critical Care for Endotoxemia.
About Spectral Diagnostics
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity
Assay, the only FDA approved diagnostic for the measurement of endotoxin.
Spectral technologies provide accurate and timely information to clinicians
enabling the early initiation of appropriate and targeted therapy. Spectral is
listed on TSX under the symbol SDI.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
For further information:
For further information: Dr. Paul Walker, President & CEO, (416)
626-3233 ex. 2100; Casey Gurfinkel, Investor Relations, (416) 815-0700 ext.